{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:01:38Z","timestamp":1789884098102,"version":"4.0.1"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1070,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1111\/bjd.12025","type":"journal-article","created":{"date-parts":[[2012,9,27]],"date-time":"2012-09-27T15:38:23Z","timestamp":1348760303000},"page":"710-713","source":"Crossref","is-referenced-by-count":42,"title":["Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal"],"prefix":"10.1093","volume":"167","author":[{"given":"Ph. I.","family":"Spuls","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Hooft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,9,26]]},"reference":[{"key":"10.1111\/bjd.12025-BIB1|cit1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20041257","article-title":"IL-23 drives a pathogenic T-cell population that induces autoimmune inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J Exp Med"},{"key":"10.1111\/bjd.12025-BIB2|cit2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s11926-007-0075-1","article-title":"Pathophysiology of psoriasis: recent advances on IL23 and Th17 cytokines","volume":"9","author":"Fitch","year":"2007","journal-title":"Curr Rheumatol Rep"},{"key":"10.1111\/bjd.12025-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1056\/NEJMe1201071","article-title":"To be 17 again - anti-interleukin-17 treatment for psoriasis","volume":"366","author":"Waisman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.12025-BIB4|cit4","doi-asserted-by":"crossref","DOI":"10.1007\/s12016-012-8307-1","article-title":"Role of IL-17 in psoriasis and psoriatic arthritis","author":"Raychaudhuri","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1111\/bjd.12025-BIB5|cit5","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/art.27334","article-title":"LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis. A phase I randomized, double-blind, placebo-controlled, proof of concept study","volume":"62","author":"Genovese","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1111\/bjd.12025-BIB6|cit6","doi-asserted-by":"crossref","first-page":"ra72","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1111\/bjd.12025-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.12025-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","article-title":"Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis","volume":"366","author":"Leonardi","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.12025-BIB9|cit9","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"10.1111\/bjd.12025-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1398-9995.2012.02874.x","article-title":"Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. Core outcome measures for atopic eczema research","volume":"67","author":"Schmitt","year":"2012","journal-title":"Allergy"},{"key":"10.1111\/bjd.12025-BIB11|cit11","first-page":"c869","article-title":"The Harmonizing Outcome Measures for Eczema (HOME) initiative","volume":"340","author":"Schmitt","year":"2010","journal-title":"BMJ"},{"key":"10.1111\/bjd.12025-BIB12|cit12","first-page":"1448","article-title":"Proceedings of OMERACT 10, the International Consensus Conference on Outcome Measures in Rheumatology Clinical Trials. May 4-8, 2010. Kota Kinabalu, Borneo","volume":"38","year":"2011","journal-title":"J Rheumatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.12025","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.12025\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:02:46Z","timestamp":1676383366000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/167\/4\/710\/6614030"}},"subtitle":["ORIGINAL ARTICLE: Papp KA, Leonardi C, Menter A et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012; 366: 118"],"short-title":[],"issued":{"date-parts":[[2012,9,26]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,10]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.12025","relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9,26]]}}}